Not Yet RecruitingPhase 2ACTRN12609001015235

Nephro-protective effects of L-amino acids in critically ill patients. A phase II multicentre randomised controlled trial.

Nephro-protective effects of L-amino acids versus standard care/usual care in critically ill adult patients at risk of developing acute kidney injury. A phase II multi-centre randomised controlled trial.

Sponsor

National Health and Medical Research Council (NHMRC)

Enrollment

474 participants

Start Date

Jan 1, 2010

Study Type

Interventional

Conditions

Critical Illness Intensive Care Unit (ICU) Patients

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether giving amino acids (protein building blocks) through an IV can protect the kidneys of critically ill patients in intensive care. Adults aged 18 and over who have a central IV line, are expected to stay in the ICU for at least 3 days, and do not have pre-existing kidney disease may be eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Supplementary infusion of L-amino acids to achieve 2g/kg/day total protein intake on each day for the entire duration of Intensive Care Unit (ICU) stay

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609001015235